首頁 › 非小細胞肺癌 › 印第安納 › Fort Wayne
Fort Wayne, IN 的 非小細胞肺癌 臨床試驗
17 項針對 非小細胞肺癌 的研究正在 Fort Wayne（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
招募中2/3 期
- Parkview Research Center /ID# 277651, Fort Wayne
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
招募中1/2 期
- Parkview Comprehensive Cancer Center /ID# 271879, Fort Wayne
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Parkview Regional Medical Center, Fort Wayne
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
招募中3 期
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
招募中3 期
- Parkview Research Center at Parkview Regional Medical Center ( Site 0089), Fort Wayne
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
招募中3 期
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
招募中3 期
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
招募中2/3 期
- Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
招募中3 期
- Research Site, Fort Wayne
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
招募中3 期
- Research Site, Fort Wayne
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
招募中1 期
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
招募中3 期
- Parkview Packnett Family Cancer Institute, Fort Wayne
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne
BostonGene and Exigent Genomic INsight Study
招募中觀察性研究
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Fort Wayne 的其他研究
- 卵巢癌8 項研究
- 癌症（所有類型）7 項研究
- 慢性淋巴性白血病7 項研究
- 乳癌7 項研究
- 肺癌6 項研究
- 轉移性癌症6 項研究
- 子宮內膜癌5 項研究
- 黑色素瘤4 項研究
- 頭頸部鱗狀細胞癌4 項研究
- 三陰性乳癌4 項研究
- 大腸直腸癌4 項研究
- 多發性骨髓瘤4 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。